You may already know the clinical benefits of home NIV, but now discover the significant cost savings this new approach could bring to your organization.
Emerging evidence has reinforced the use of home-based noninvasive ventilation (NIV) to treat patients with chronic hypercapnic COPD. This new methodology was proven in the recent HOT-HMV study.1 And now, outcomes of a study published in Value in Health make the clinical and financial benefits of combination therapy truly impossible to ignore.2
Collectively, the reports demonstrate that when you center care on patients, the organizational cost savings follow.
We need to reimagine the way we provide care to patients across the entire care continuum and throughout every stage of disease. We’re not relegated to just medication; we’ve got much more in our wheelhouse.”
Teofilo Lee-Chiong, MD
Pulmonologist and Chief Medical Liaison
Better for patients
Today, nearly 25% of COPD patients will be readmitted following an acute exacerbation.3 This impacts disease morbidity, worsens their quality of life and drives increased costs and penalties for health systems.
Recently, NIV usage has increased in hospitals to treat these exacerbations in patients with severe COPD. But, when patients are discharged, they are often armed only with oxygen, medication and an inhaler.
De-escalating the level of care upon discharge is thought to be the culprit responsible for many readmissions.
Continue to the full article.
1. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177-2186.
2. Coughlin S, Peyerl FW, Munson SH, Ravindranath AJ, Lee-Chiong TL. Cost savings from reduced hospitalizations with use of home noninvasive ventilation for COPD. Value Health. 2017;20(3):379-387.
3. Shah T, Press VG, Huisingh-Scheetz M, White SR. COPD readmissions: addressing COPD in the era of value-based health care. Chest. 2016;150(4):916-926.
Excerpt and photo printed with permission from Philips Respironics
Be the first to comment